secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001193125-23-007186
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion details 2023 milestones: AML/ALL data, KRAS trial, diabetes data, BMF-500 IND
--------------------------------------------------------------------------------

- Plan to present initial COVALENT-101 data (BMF-219 in AML/ALL) in H1 2023; first patient in COVALENT-102 (KRAS solid tumors) dosed Jan 2023.
- IND for BMF-500 (FLT3 inhibitor) expected in H1 2023 for COVALENT-103 trial in acute leukemia.
- Phase II COVALENT-111 (BMF-219 in Type 2 diabetes) initial data from first two cohorts by end of Q1 2023.
- Third development candidate from FUSION platform to be announced in H1 2023.
- BMF-219 is first menin inhibitor in clinical development for solid tumors and diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523007186/0001193125-23-007186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523007186/d417295d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-007186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer